China-based vaccine specialist CanSino Biologics Inc. (HKG: 6185) announced that its absorbed diphtheria, tetanus, acellular pertussis (DTcP), Haemophilus influenzae type b (Hib), and Group ACYW135 meningococcal (MCV4) combined vaccine has received clinical trial approval from the National Medical Products Administration (NMPA). The single-dose vaccine aims to provide comprehensive immune protection against multiple pathogens.
Vaccine Profile
The DTcP Hib MCV4 combined vaccine integrates components targeting diphtheria, tetanus, pertussis, Hib, and meningococcal infections. CanSino’s DTcP vaccine is currently in Phase III trials, while its Hib vaccine is in Phase I. Data from these trials are being leveraged to develop the combined vaccine, which the firm aims to position as a differentiated product in the market.-Fineline Info & Tech
Leave a Reply